Sun Pharma Q4 net at Rs 820 cr

Appoints Israel Makov as the chairman in place of Dilip Shanghvi

Sun Pharmaceutical Industries Ltd today reported a consolidated of Rs 820.21 crore for the fourth quarter ended March 31, 2012.

The company had posted a of Rs 442.75 crore for the same period of previous fiscal, said in a filing to the BSE.

of the company stood at Rs 2,329.93 for the fourth quarter ended March 31, 2012 as against Rs 1,463.28 crore during the corresponding period of previous fiscal.

For the year ended March 31, 2012, the company posted a of Rs 2,587.25 crore compared to Rs 1,816.06 crore in 2010-11.

"Taro Pharmaceutical Industries became a subsidiary of the company on September 20, 2010 therefore the figures for the current fiscal are not comparable with the corresponding figures for the previous financial year," the company said.

The company's board, which met today, recommended a dividend of Rs 4.25 per equity share of Re 1 each for the financial year ended March 31, 2012.

In a separate filing the company said it has appointed as the Chairman of the company in place of Dilip Shanghvi, who has has stepped down from the position while continuing to remain as the company's Managing Director.

The company's board has also appointed Makov, a resident of Israel, as an additional director on the company's board, it said.

Shares of today closed at Rs 565.65 on the BSE, down 0.68% from its previous close.

image
Business Standard
177 22
Business Standard

Sun Pharma Q4 net at Rs 820 cr

Appoints Israel Makov as the chairman in place of Dilip Shanghvi

Press Trust of India  |  New Delhi 

Sun Pharmaceutical Industries Ltd today reported a consolidated of Rs 820.21 crore for the fourth quarter ended March 31, 2012.

The company had posted a of Rs 442.75 crore for the same period of previous fiscal, said in a filing to the BSE.

of the company stood at Rs 2,329.93 for the fourth quarter ended March 31, 2012 as against Rs 1,463.28 crore during the corresponding period of previous fiscal.

For the year ended March 31, 2012, the company posted a of Rs 2,587.25 crore compared to Rs 1,816.06 crore in 2010-11.



"Taro Pharmaceutical Industries became a subsidiary of the company on September 20, 2010 therefore the figures for the current fiscal are not comparable with the corresponding figures for the previous financial year," the company said.

The company's board, which met today, recommended a dividend of Rs 4.25 per equity share of Re 1 each for the financial year ended March 31, 2012.

In a separate filing the company said it has appointed as the Chairman of the company in place of Dilip Shanghvi, who has has stepped down from the position while continuing to remain as the company's Managing Director.

The company's board has also appointed Makov, a resident of Israel, as an additional director on the company's board, it said.

Shares of today closed at Rs 565.65 on the BSE, down 0.68% from its previous close.

RECOMMENDED FOR YOU

Sun Pharma Q4 net at Rs 820 cr

Appoints Israel Makov as the chairman in place of Dilip Shanghvi

The company had posted a net profit of Rs 442.75 crore for the same period of previous fiscal, Sun Pharma said in a filing to the BSE.

Sun Pharmaceutical Industries Ltd today reported a consolidated of Rs 820.21 crore for the fourth quarter ended March 31, 2012.

The company had posted a of Rs 442.75 crore for the same period of previous fiscal, said in a filing to the BSE.

of the company stood at Rs 2,329.93 for the fourth quarter ended March 31, 2012 as against Rs 1,463.28 crore during the corresponding period of previous fiscal.

For the year ended March 31, 2012, the company posted a of Rs 2,587.25 crore compared to Rs 1,816.06 crore in 2010-11.

"Taro Pharmaceutical Industries became a subsidiary of the company on September 20, 2010 therefore the figures for the current fiscal are not comparable with the corresponding figures for the previous financial year," the company said.

The company's board, which met today, recommended a dividend of Rs 4.25 per equity share of Re 1 each for the financial year ended March 31, 2012.

In a separate filing the company said it has appointed as the Chairman of the company in place of Dilip Shanghvi, who has has stepped down from the position while continuing to remain as the company's Managing Director.

The company's board has also appointed Makov, a resident of Israel, as an additional director on the company's board, it said.

Shares of today closed at Rs 565.65 on the BSE, down 0.68% from its previous close.

image
Business Standard
177 22

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard